This research study on the global premenstrual dysphoric disorder market
throws light on the factors that drive this industry. It throws light
on the challenges that hamper the growth and performance of the
premenstrual dysphoric disorder market in some of the major geographical
regions. With an exhaustive collection of graphical and tabular
representations, this market study analyzes and evaluates the ongoing
trends in the premenstrual dysphoric disorder market. The historical and
the present day data and market information presented in this report
enables one to evaluate the progress made by this industry so far.
With the help of analytical tools such as
the value chain analysis and the Porter’s five forces analysis, this
research report examines the macro and micro level factors which have a
direct impact on the global premenstrual dysphoric disorder market. The
information, data, facts, and statistical figures presented in this
research report are based on primary and secondary sources of
information and valuable inputs from industry experts.
The report offers detailed insights into
the factors that are expected to drive this industry in the forthcoming
years. Also, it throws light on the latest technological developments
that are taking place in this industry. The research report offers a
comprehensive overview of the competitive landscape of the premenstrual
dysphoric disorder market via company profiling. The report analyzes
each company on the basis of parameters such as the key company facts,
SWOT analysis, business strategies, and the recent developments.
Overview of the premenstrual dysphoric disorder market
The rising incidence of premenstrual
dysphoric disorder can be attributed to the rising unhygienic lifestyle
of women. This is in fact, is the main factor driving the global
premenstrual dysphoric disorder market. The growth of this market in the
developing world is mainly propelled by greater awareness amongst women
about the prevalence of premenstrual dysphoric disorders. Furthermore,
the easy availability of premenstrual dysphoric disorder products is
anticipated to drive this market in the years to come.
PMDD (premenstrual dysphoric disorder)
refers to a medical condition in women which is characterized by
tension, anxiety, irritability, and depression prior to menstruation.
Experts and researchers are yet to find out the reason behind such a
medical condition. However, hormonal changes and vitamin deficiency are
few factors that lead to this disorder.
Unavailability of effective diagnostic
tests is a glaring restraint in this market which in turn has an adverse
impact on the overall demand in the global premenstrual dysphoric
disorder market. As per the U.S. National Library of Medicine, 3% – 8%
women in the U.S. are affected by premenstrual dysphoric disorder before
menstruation.
Europe and North America are the key
regional markets because of high incidence of premenstrual dysphoric
disorder in these regions. Owing to lack of widespread awareness, Asia
Pacific holds immense growth potential in the overall market for
premenstrual dysphoric disorder. This region is yet to be tapped. It is
anticipated that the Asia Pacific market will grow substantially during
the forecast period owing to improvements in healthcare infrastructure.
Companies mentioned in the research report
The key companies operating in the global
premenstrual dysphoric disorder market are Bristol Meyer Squibb, Endo
Pharmaceuticals, Merck and Co., Novartis AG, Pfizer, Inc., Cipla
Laboratories, GlaxoSmithKline plc, Johnson & Johnson, Abbott
Healthcare, Eli Lilly and Company, Dr. Reddy’s Laboratories Ltd., and
Forest Laboratories,
No comments:
Post a Comment